Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway

详细信息    查看全文

• 作者：Sebastian F. Schoppmann^a ; Andrea Beer^a ; Nadine Nirtl^b ; Ahmed Ba-Ssalamah^c ; Thomas Brodowicz^d ; Berthold Streubel^e ; Peter Birner^f ; ^{peter.birner@meduniwien.ac.at}
• 关键词：PEBP1 ; RKIP ; ETV1 ; MEK ; GIST ; Prognosis
• 刊名：Cancer Letters
• 出版年：2013
• 出版时间：10 July, 2013
• 年：2013
• 卷：335
• 期：1
• 页码：26-30
• 全文大小：1079 K

文摘

Aim of this study was to investigate phosphatidylethanolamine binding protein 1 (PEBP1) in GIST and its relations with MEK1/2 activation and ETV1 by immunohistochemistry. Loss of PEBP1 was found in 22/161 (13.7 % ) GIST, was associated with clinical risk factors and with a trend towards shorter disease free survival, but not with pMEK1/2 and ETV1 expression. So downregulation of PEBP1 does not activate the Ras-Raf-1-MEK1/2-ERK1/2 pathway by phosphorylation of MEK1/2 and does not influence ETV1 expression in GIST. Loss of PEBP1 associates with clinical risk factors, but since no significant influence on survival was found, further studies are required.